Promising new combo targets Hard-to-Treat breast cancer
NCT ID NCT06042894
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 26 times
Summary
This study tests two experimental drugs, SI-B003 alone or combined with BL-B01D1, in people with advanced HER2-negative breast cancer that has spread or cannot be removed. The goal is to see if these treatments can shrink tumors or slow the disease. About 58 adults who have not responded to standard therapies will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.